Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)

Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study) / Van Wijmeersch, B., Barone, D., Broadley, S., Dive, D., Hupperts, R., Lycke, J., Massacesi, L., Montalban, X., Naismith, R.T., Pandey, K., Schippling, S., Vermersch, P., Chung, L., Daizadeh, N., Rodriguez, C.E., Nakamura, K., Wiendl, H.. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - STAMPA. - 24:(2018), pp. 488-489.

Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)

BARONE, DOMENICA;Massacesi, L;
2018

Abstract

Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)
2018
Van Wijmeersch, B; Barone, D; Broadley, S; Dive, D; Hupperts, RMM; Lycke, J; Massacesi, L; Montalban, X; Naismith, RT; Pandey, K; Schippling, S; Verme...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1177415
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact